Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT06024356·Not applicable·OBSERVATIONAL

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Thymosin Alpha-1OtherCompleted

Status

Completed

Phase

Not applicable

Enrollment

47

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.

Full detailed description

Study Purpose 1. To evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer. 2. To explore the effects of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin on the immune microenvironment of locally advanced mid-low rectal cancer. Study Design: A single-center, retrospective, controlled study Subjects were divided into two groups according to whether or not they received thymalfasin: group 1 was treated with neoadjuvant chemoradiotherapy combined with PD-1 inhibitor, and group 2 was treated with neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin. Subjects received long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks). Thymalfasin was started on the first day of neoadjuvant chemoradiotherapy, 1.6 mg subcutaneously twice a week until the end of the last neoadjuvant treatment. Enrollment: preoperative Tα1 (n=14), postoperative Tα1 (n=7), or no Tα1 (n=26) Study Population: locally advanced mid-low rectal cancer Primary Endpoint: 3-y DFS, pCR rate Exploratory endpoint: Paraffin specimens were collected from biopsies before neoadjuvant therapy and after surgery in patients meeting the inclusion criteria. The expression of CD86, CD163, CD4+T，CD8+T，PD-1 were detected.

Interventions

Treatment arms and agents.

DRUG

Thymalfasin

Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.

Timeline

From registration to results.

  1. First posted

    Sep 6, 2023

  2. Study start

    Sep 20, 2023

  3. Primary completion

    Apr 30, 2026

  4. Study completion

    May 15, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Jun 18, 2026

Outcomes

What the study measures.

Primary outcomes

3-y DFS

Time frame · 3 years

3-y DFS was defined as the time from surgery to disease recurrence, death, or last follow-up within 3 years

pathologic complete response

Time frame · 1 year

All the enrolled patients will receive total mesorectal excision (TME) 7-9 weeks after the end of long course radiotherapy. The rectal specimens will be evaluated by the pathologists who are experienced on the rectal cancer diagnosis according to the 1997 Dworak grading system. The rectal cancer will be classified into 5 grades. Grade 0-3 will be considered as non-pCR while grade 4 represent pCR.

Secondary outcomes

neoadjuvant rectal (NAR) score

Time frame · 1 year

The neoadjuvant rectal (NAR) score is a promising indicator of survival after preoperative chemoradiotherapy for rectal cancer. The NAR score was calculated according to the following formula: NAR score = \[5pN - 3(cT - pT) + 12\]2⁄9.61. (clinical tumor (cT) stage, pathologic tumor (pT) stage, pathologic nodal (pN) stage)

tumor regression grade（TRG）

Time frame · 1 year

AJCC 8th TRG classification. TRG 0: No viable cancer cells left in the specimen; complete regression. TRG 1: Minimal residual cancer cells present; extensive regression with a minimal number of tumor cells. TRG 2: Moderate residual cancer cells present; substantial regression with a significant number of tumor cells. TRG 3: Minimal or no regression; no significant tumor cell response to treatment; majority of tumor still present.

objective response rate (ORR)

Time frame · 1 year

ORR is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORR rate is the sum of complete response (CR) and partial response (PR)

R0 resection rate

Time frame · 1 year

During the surgical process, the surgeon will evaluate the level of cancer resection. It will be classified as R0, R1, R2 resection. Therefore, we can calculate R0 resection rate.

anal preservation rate

Time frame · 1 year

the surgeon will decide whether the anal can be preserved on the basis of the rectal cancer and intraoperative situation. anal preservation rate is the percentage of patients who achieve anal preservation.

disease free survival (DFS)

Time frame · 3 year

During the 3-year follow-up, the percentage of the patients who is disease free.

local recurrence free survival

Time frame · 3 year

During the 3-year follow-up, the percentage of local recurrence.

overall survival (OS)

Time frame · 3 year

During the 3-year follow-up, the percentage of the patients who is sill survival at the end of follow-up.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patients with rectal adenocarcinoma must satisfied all the following conditions: 1. Stage II/III LARC (cT1-4aN0-2M0); 2. Tumor distal location≤10 cm from anal verge (MRI diagnosed); * Patients regardless of gender with aged≥18 years * ECOG score of 0 or 1 * Physical and viscera function of patients can withstand major abdominal surgery Exclusion Criteria: * Current or previous active malignancy other than rectal cancer； * Patients underwent major surgery within 4 weeks prior to neoadjuvant therapy； * Patients have any condition affects the absorption of capecitabine through gastrointestinal tract； * Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases; * Patients with severe concomitant diseases with estimated survival≤5 years； * Patients with present or previous moderate or severe liver and kidney damage； * Patients preparing for or previously received organ or bone marrow transplant； * Patients who have received immunosuppressive or systemic hormone therapy within 1 month prior to the start of neoadjuvant therapy； * Patients with congenital or acquired immune deficiency (such as HIV infection)； * Pregnant or lactating women.

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Beijing Friendship Hospital, Capital medical University

Beijing, Xicheng Dis, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Thymosin Alpha-1.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsThymosin Alpha-1 trial dashboard →MarketThymosin Alpha-1 comparison →Research vendor recordAscension Peptides →Research vendor recordNura Peptide →Research vendor recordGlacier Aminos →Research vendor recordEZ Peptides →